- Home
- EPIX
EPIX
ESSA Pharma Inc.
as 07-26-2024 4:00pm EST
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
| Founded: | 2009 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 228.0M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 29.1K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.58 - $11.67 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ESSA Pharma Inc. (EPIX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Virsik Peter | EPIX | Chief Operating Officer | May 6 '24 | Sell | $6.95 | 694 | $4,823.30 | 11,246 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Apr 5 '24 | Sell | $7.94 | 694 | $5,510.36 | 11,940 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Mar 5 '24 | Sell | $8.98 | 694 | $6,232.12 | 12,634 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Feb 6 '24 | Sell | $10.29 | 72,782 | $748,926.78 | 13,328 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Feb 5 '24 | Sell | $9.25 | 694 | $6,419.50 | 13,328 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Feb 5 '24 | Sell | $10.04 | 500 | $5,020.00 | 13,328 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Jan 16 '24 | Sell | $10.01 | 1,718 | $17,197.18 | 14,022 | SEC Form 4 |
| Virsik Peter | EPIX | Chief Operating Officer | Jan 5 '24 | Sell | $6.11 | 699 | $4,270.89 | 14,022 | SEC Form 4 |
| Parkinson David Ross | EPIX | Chief Executive Officer | Dec 14 '23 | Buy | $2.30 | 9,223 | $21,212.90 | 65,675 | SEC Form 4 |
| BERGER FRANKLIN M | EPIX | Director | Nov 21 '23 | Buy | $5.73 | 23,259 | $133,274.07 | 784,404 | SEC Form 4 |
Latest ESSA Pharma Inc. News
EPIX Breaking Stock News: Dive into EPIX Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
Simply Wall St.
25 days ago
With 40% stake, ESSA Pharma Inc. (NASDAQ:EPIX) seems to have captured hedge funds investors' interest
CNW Group
2 months ago
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
PR Newswire
2 months ago
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
Zacks Small Cap Research
2 months ago
EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24
Simply Wall St.
2 months ago
Insider Stock Buying Reaches US$709.0k On ESSA Pharma
Associated Press Finance
2 months ago
ESSA Pharma: Fiscal Q2 Earnings Snapshot
PR Newswire
2 months ago
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
Compare EPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EPIX ESSA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.